India’s Pharma Stocks Climb as CDMO Contracts Replace the Generic Trade as the Growth Driver
India's Nifty Pharma index has outperformed the broader market by 14 percentage points in 2026, but the re-rating is not driven by generic API volume -- it is driven by CDMO contract

Follow